http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#Head http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#assertion http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#provenance http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#pubinfo http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#assertion http://purl.obolibrary.org/obo/DOID_8469 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8469 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00558 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association http://www.w3.org/2000/01/rdf-schema#label relenza an influenza virus neuraminidase inhibitor nai is indicated for treatment of acute uncomplicated influenza type a and b infections 1 1 prophylaxis of influenza 1 2 important limitations of use not recommended for treatment or prophylaxis of influenza in 5 1 not proven effective for 1 3 1 3 not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 1 3 relenza zanamivir inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days relenza is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older see warnings and precautions 5 1 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00558 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#provenance http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#pubinfo http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig http://purl.org/nanopub/x/hasSignature D8JBLUi/KjWeRBuIhOSHbhHP0zPDwmbvDFmkkpI1VByhDSYuDzixpk7qGFqntr/GaboGlDAexBWZYnnUUWwuAUTrmVuXP4cJlP311DyPjLLQAeCiXEqbyPLhPns4xstJjmjTph9MlvYUtPlw2a1ksmjfyRomwdTVJq+QTrgmOZc= http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://purl.org/dc/terms/created 2021-06-15T18:36:10.185+02:00 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAhN3pQJksh_0KrbKdsLTq8cuK0dnZRmdjPDlJhr9oxl0 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs